Rituxan® (Rituximab) Medication Precertification Request
Transcript of Rituxan® (Rituximab) Medication Precertification Request
Rituxan® (rituximab) Medication Precertification Request
Aetna Precertification Notification 503 Sunport Lane, Orlando, FL 32809
Phone: 1-866-503-0857 FAX: 1-888-267-3277
Page 1 of 3
For Medicare Advantage Part B: FAX: 1-844-268-7263
(All fields must be completed and return both pages for precertification review)
Please indicate: Start of treatment, start date: Continuation of therapy,/ / date of last treatment: / /
Precertification Requested By: Phone: Fax:
A. PATIENT INFORMATION
First Name: Last Name:
Address: City: State: ZIP:
Home Phone: Work Phone: Cell Phone:
DOB: Allergies: E-mail:
Current Weight: lbs or kgs Height: inches or cms
B. INSURANCE INFORMATION
Member ID #:
Group #:
Insured:
Does patient have other coverage? Yes No
If yes, provide ID#: Carrier Name:
Insured:
Medicare: Yes No If yes, provide ID #: Medicaid: Yes No If yes, provide ID #:
C. PRESCRIBER INFORMATION
First Name: Last Name: (Check one): M.D. D.O. N.P. P.A.
Address: City: State: ZIP:
Phone: Fax: St Lic #: NPI #: DEA #: UPIN:
Provider E-mail: Office Contact Name: Phone:
Specialty (Check one): Rheumatologist Other:
D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION
Place of Administration:
Self-administered Physician’s Office
Outpatient Infusion Center Phone:
Center Name:
Home Infusion Center Phone:
Agency Name:
Administration code(s) (CPT):
Address:
Dispensing Provider/Pharmacy: Patient Selected choice
Physician’s Office Retail Pharmacy
Specialty Pharmacy Mail Order
Other:
Name:
Address:
Phone: Fax:
TIN: PIN:
E. PRODUCT INFORMATION
Rituxan: Dose: Directions for Use:
F. DIAGNOSIS INFORMATION - Please indicate primary ICD code and specify any other any other where applicable (*).
Primary ICD Code: Other ICD Code:
G. CLINICAL INFORMATION - Required clinical information must be completed for ALL precertification requests.
Is/ Will rituximab (Rituxan) be used concomitantly with apremilast, tofacitinib, or other biologic DMARDs (e.g., adalimumab, infliximab)? Yes No
Acute lymphoid leuke mia
Does the patient have a documented diagnosis of Philadelphia chromosome-negative acute lymphoid leukemia (ALL)? Yes No
Is rituximab (Rituxan) being used as induction/consolidation therapy? Yes
No
Autoimmune hemolytic anemia
Does the patient have a documented diagnosis of refractory autoimmune hemolytic anemia? Yes No
Anti-neutrophil cytoplasmic antibody-associated (ANCA-associated) vasculitides
Please indicate which of the following applies to the patient: Wegener granulomatosis Churg-Strauss syndrome
microscopic polyangiitis pauci-immune glomerulonephritis
Has the patient had an inadequate response to cyclophosphamide? Yes No
Will Rituxan be given in conjunction with glucocorticoids? Yes No
Autoimmune blistering diseases, corticosteroid-refractory
Please select which applies to the patient: pemphigus vulgaris pemphigus folliaceus bullous pemphigoid cicatricial pemphigoid
epidermolysis bullosa acquisita paraneoplastic pemphigus None of the above
Castleman's disease
Does the patient have a documented diagnosis of multicentric Castleman’s disease (angiofollicular lymph node hyperplasia)? Yes No
Chronic or small lymphocytic leukemia
Please select which applies to the patient: chronic lymphocytic leukemia (CLL) small lymphocytic leukemia
Cryoglobulinemia
Does the patient have a documented diagnosis of cryoglobulinemia? Yes No
Is there clinical documentation that the treatment with corticosteroids and other immunosuppressive agents was ineffective? Yes No
Graft versus host disease, chronic
There is documentation that rituximab (Rituxan) is being used as last-resort treatment for chronic graft versus host disease (GVHD)? Yes No
Hairy cell leukemia
Please select which applies to the patient: relapsed hairy cell leukemia refractory hairy cell leukemia Other, please explain:
Was treatment with at least two courses of cladribine ineffective? Yes
Please provide the date range of course #1: Date range:
Please provide the date range of course #2: Date range:
No
/ / - / /
/ / /
Continued on next page
/ -
GR-68535 (11-17)
/ / - / /
/ / - / /
Aetna Precertification Notification Rituxan® (rituximab) Medication 503 Sunport Lane, Orlando, FL 32809
Phone: 1-866-503-0857 Precertification Request FAX: 1-888-267-3277
Page 2 of 3 (All fields must be completed and return both pages for precertification review) For Medicare Advantage Part B:
FAX: 1-844-268-7263
/ / - / /
/ / - / /
/ / - / /
/ / - / /
/ / - / /
/ / - / /
/ / - / /
Patient First Name Patient Last Name Patient Phone Patient DOB
G. CLINICAL INFORMATION (Continued) - Required clinical information must be completed for ALL precertification requests.
Heart and solid organ transplant
Please select which applies to the patient: heart transplant recipient other solid organ transplant recipient
Is there a documentation that rituximab (Rituxan) is being used for treatment or prevention (desensitization) of highly sensitized patients with
antibody mediated rejection in heart transplant recipients and other solid organ transplant recipients?
Yes No
Immune or idiopathic thrombocytopenic purpura
Does the patient have a documented diagnosis of refractory immune or idiopathic thrombocytopenic purpura (ITP)?
refractory immune thrombocytopenic purpura idiopathic thrombocytopenic purpura (ITP)
Yes No
Kidney transplant, rejection prophylaxis
Is rituximab (Rituxan) being used as rejection prophylaxis in sensitized kidney transplant recipients with donor specific antibodies? Yes No
Lymphocyte-predominant Hodgkin's lymphoma
Does the patient have a documented diagnosis of lymphocyte-predominant Hodgkin’s lymphoma? Yes No
Multiple Sclerosis
Please indicate the type of multiple sclerosis the patient has been diagnosed with:
Relapsing-remitting MS (RRMS) Secondary-progressive MS (SPMS) Primary-progressive MS (PPMS) Progressive-relapsing MS (PRMS)
Has the patient discontinued other medications used for treating MS (not including Ampyra)? Yes No
Is there documentation that Rituxan is being used as last-resort treatment? Yes No
Has the patient had an inadequate response to medications used to treat multiple sclerosis? Yes
Which of the following MS medications has the patient tried and had a documented failure to?
alemtuzumab (Lemtrada) : Please indicate the date range of trial:
Please define the failure of therapy*: Increasing relapses Lesion progression by MRI Worsening of Disability Other:
daclizumab (Zinbryta) : Please indicate the date range of trial:
Please define the failure of therapy*: Increasing relapses Lesion progression by MRI Worsening of Disability Other:
dimethyl fumarate (Tecfidera) : Please indicate the date range of trial:
Please define the failure of therapy*: Increasing relapses Lesion progression by MRI Worsening of Disability Other:
glatiramir acetate (Copaxone or Glatopa): Please indicate the date range of trial:
Please define the failure of therapy*: Increasing relapses Lesion progression by MRI Worsening of Disability Other:
fingolimod (Gilenya): Please indicate the date range of trial:
Please define the failure of therapy*: Increasing relapses Lesion progression by MRI Worsening of Disability Other:
interferon beta-1a (Avonex, Rebif): Please indicate the date range of trial:
Please define the failure of therapy*: Increasing relapses Lesion progression by MRI Worsening of Disability Other:
interferon beta-1b (Betaseron, Extavia): Please indicate the date range of trial:
Please define the failure of therapy*: Increasing relapses Lesion progression by MRI Worsening of Disability Other:
natalizumab (Tysabri): Please indicate the date range of trial: / / - / /
Please define the failure of therapy*: Increasing relapses Lesion progression by MRI Worsening of Disability Other:
ocrelizumab (Ocrevus): Please indicate the date range of trial:
Please define the failure of therapy*: Increasing relapses Lesion progression by MRI Worsening disability Other:
teriflunomide (Aubagio): Please indicate the date range of trial:
Please define the failure of therapy*: Increasing relapses Lesion progression by MRI Worsening of Disability Other:
No
* Increasing relapses: defined as two or more r elapses in a year, or one sev ere relapse associated with either p oor recovery or MRI lesion progression
* Lesion progression by MRI: defined as increased number or volume of gadolinium-enhancing lesions, T2 hyperintense lesions or T1 hypointense lesions
* Worsening disability: defined b y sustained worsening of E xpanded Disability S tatus Scale ( EDSS) sc ore or n eurological examination findings
Neuromyelitis optica
Does the patient have a documented diagnosis of neuromyelitis optica? Yes No
Was the treatment with at least one immunotherapy was ineffective? Yes No
Non-Hodgkin's lymphoma
Does the patient have a documented diagnosis of non-Hodgkin’s lymphoma (NHL)? Yes No
Opsoclonus-myoclonus-ataxia (opsoclonus myoclonus syndrome)
Does the patient have a documented diagnosis of opsoclonus-myoclonus-ataxia (OMA) associated with neuroblastoma? Yes
/ / - / /
/ / - / /
/ / - / /
No
Is the patient refractory to steroids, chemotherapy and intravenous immunoglobulins? Yes
Please provide the names and date ranges of medications tried:
Medication: Dates:
Medication: Dates:
Medication: Dates:
No
Post-transplant lymphoproliferative disorder
Does the patient have a documented diagnosis of post-transplant lymphoproliferative disorder? Yes No
Continued on next page
GR-68535 (11-17)
-
Aetna Precertification Notification Rituxan® (rituximab) Medication 503 Sunport Lane, Orlando, FL 32809
Phone: 1-866-503-0857 Precertification Request FAX: 1-888-267-3277
Page 3 of 3 (All fields must be completed and return both pages for precertification review) For Medicare Advantage Part B:
FAX: 1-844-268-7263
Patient First Name Patient Last Name Patient Phone Patient DOB
G. CLINICAL INFORMATION (Continued) Required clinical information must be completed for ALL precertification requests.
Sjögren syndrome
Does the patient have a documented diagnosis of Sjögren’s syndrome?Yes No
Was treatment with corticosteroids and other immunosuppressive agents ineffective?Yes
Please provide the names and dates of the corticosteroids and other immunosuppressive agents used:
Medication: Dates: / / - / /
Medication: Dates: / / - / /
No
Thrombotic thrombocytopenic purpura
Does the patient have a documented diagnosis of refractory thrombotic thrombocytopenic purpura (TTP)? Yes No
Waldenstrom’s macroglobulinemia
Does the patient have a documented diagnosis of Waldenström macroglobulinemia? Yes No
Rheumatoid Arthritis
Please indicate the severity of the patient’s rheumatoid arthritis: Mild Moderate Severe
Is there evidence that the disease is active? Yes No
Was treatment with Enbrel ineffective? Yes
Please provide the date range of the trial: Date range:
Was the treatment with Enbrel not tolerated or contraindicated?
/ / - / /
not tolerated contraindicated Yes No
No
Was treatment with Inflectra ineffective? Yes
Please provide the date range of the trial: Date range:
Was the treatment with Inflectra not tolerated or contraindicated? not tolerated contraindicated Yes No
No
/ / - / /
Was treatment with Remicade ineffective? Yes
Please provide the date range of the trial: Date range: / / - / /
Was the treatment with Remicade not tolerated or contraindicated? not tolerated contraindicated Yes No
No
/ / - / /
Was treatment with Renflexis ineffective? Yes
Please provide the date range of the trial: Date range:
Was the treatment with Renflexis not tolerated or contraindicated? not tolerated contraindicated Yes No
No
Was treatment with Simponi ineffective? Yes
/ / - / /Please provide the date range of the trial: Date range:
Was the treatment with Simponi not tolerated or contraindicated? not tolerated contraindicated Yes No
No
Was treatment with Simponi Aria ineffective? Yes
Please provide the date range of the trial: Date range:
Was the treatment with Simponi Aria not tolerated or contraindicated? not tolerated contraindicated Yes No
No
/ / - / /
Was treatment with Xeljanz/Xeljanz XR ineffective? Yes
Please provide the date range of the trial: Date range: / / - / /
Was the treatment with Xeljanz/Xeljanz XR not tolerated or contraindicated? not tolerated contraindicated Yes No
No
Will rituximab be used in combination with methotrexate?Yes No
For Continuation Request:
Is this continuation request a result of the patient receiving samples of rituximab (Rituxan)? (Sampling of Rituxan does not guarantee coverage under the provisions of the pharmacy benefit)
Yes No
For rheumatoid arthritis and multiple sclerosis only:
Please indicate the length of time on therapy:
Is there clinical documentation supporting disease stability? Yes No
Is there clinical documentation supporting disease improvement? Yes No
H. ACKNOWLEDGEMENT
Request Completed By (Signature Required): Date: / /
Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any
insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act,
which is a crime and subjects such person to criminal and civil penalties.
The plan may request additional information or clarification, if needed, to evaluate requests.
GR-68535 (11-17)